Gossamer Bio (GOSS) News Today $0.81 -0.01 (-1.47%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will TripleApril 11 at 3:11 AM | msn.comphaware® Launches Special Series of Podcast Episodes Spotlighting the Future of PH-ILD Treatment and InnovationApril 1, 2025 | finance.yahoo.comCantor Fitzgerald Forecasts Gossamer Bio FY2025 EarningsGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Gossamer Bio in a report released on Monday, March 24th. Cantor Fitzgerald analyst O. Brayer now anticipates that the company will post earnings per share of ($0.March 27, 2025 | marketbeat.comIs Gossamer Bio, Inc. (GOSS) The Hot Biotech Stock Under $5?March 26, 2025 | insidermonkey.comGossamer Bio (GOSS): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.com10 Hot Biotech Stocks Under $5March 23, 2025 | insidermonkey.comGOSSAMER BIO Earnings Preview: Recent $GOSS Insider Trading, Hedge Fund Activity, and MoreMarch 21, 2025 | nasdaq.comHC Wainwright Predicts Reduced Earnings for Gossamer BioGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Stock analysts at HC Wainwright reduced their Q1 2025 EPS estimates for shares of Gossamer Bio in a research note issued on Tuesday, March 18th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.16) per share for the quarMarch 21, 2025 | marketbeat.comBrokers Set Expectations for Gossamer Bio FY2028 EarningsGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Stock analysts at HC Wainwright lowered their FY2028 EPS estimates for shares of Gossamer Bio in a report issued on Tuesday, March 18th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.24 for thMarch 20, 2025 | marketbeat.comPlatinum Investment Management Ltd. Sells 344,613 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)Platinum Investment Management Ltd. trimmed its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 9.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,180,295 shares of the company's stock afterMarch 20, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Gossamer Bio (NASDAQ:GOSS)HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a report on Tuesday.March 19, 2025 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Receives Outperform Rating from WedbushWedbush restated an "outperform" rating and issued a $4.00 price target on shares of Gossamer Bio in a research note on Friday.March 15, 2025 | marketbeat.comMonaco Asset Management SAM Acquires 1,520,721 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)Monaco Asset Management SAM lifted its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 39.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,371,641 shares of the company's stock after bMarch 15, 2025 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Issues Quarterly Earnings Results, Hits ExpectationsGossamer Bio (NASDAQ:GOSS - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.15).March 14, 2025 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Issues Quarterly Earnings ResultsGossamer Bio (NASDAQ:GOSS - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.15) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.15).March 14, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Gossamer Bio (GOSS)March 14, 2025 | markets.businessinsider.comGossamer Bio shares rise on Q4 earnings beatMarch 13, 2025 | uk.investing.comGossamer Bio reports Q4 EPS (15c), consensus (17c)March 13, 2025 | markets.businessinsider.comGossamer Bio reports Q4 revenue $9.4M, consensus $7.0MMarch 13, 2025 | markets.businessinsider.comGossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business UpdateMarch 13, 2025 | finance.yahoo.com3 Promising Penny Stocks With Over $100M Market CapMarch 12, 2025 | finance.yahoo.comWith 60% ownership of the shares, Gossamer Bio, Inc. (NASDAQ:GOSS) is heavily dominated by institutional ownersMarch 3, 2025 | finance.yahoo.comGossamer Bio (GOSS) Projected to Post Quarterly Earnings on TuesdayGossamer Bio (NASDAQ:GOSS) will be releasing earnings before the market opens on Tuesday, March 4.February 25, 2025 | marketbeat.comGossamer Bio regains Nasdaq compliance with bid priceFebruary 22, 2025 | investing.comGossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILDFebruary 13, 2025 | seekingalpha.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | businesswire.comGossamer Bio showcases seralutinib studies at PVRI CongressFebruary 4, 2025 | msn.comGossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual CongressFebruary 3, 2025 | businesswire.comHC Wainwright Weighs in on Gossamer Bio FY2029 EarningsGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Stock analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Gossamer Bio in a research note issued on Thursday, January 30th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $0.59 forJanuary 31, 2025 | marketbeat.comGossamer Bio’s Seralutinib Advances Propel Buy Rating Amid Strategic Developments and Expansion OpportunitiesJanuary 31, 2025 | markets.businessinsider.comGossamer Bio And 2 Other Promising Penny Stocks On US ExchangesJanuary 30, 2025 | finance.yahoo.comGossamer Bio's (GOSS) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a research note on Thursday.January 30, 2025 | marketbeat.comGossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual CongressJanuary 28, 2025 | finance.yahoo.comGossamer Bio’s Strategic Focus on PAH Unmet Needs and Seralutinib Efficacy Drives Buy RatingJanuary 27, 2025 | markets.businessinsider.comCantor Fitzgerald Predicts Gossamer Bio FY2025 EarningsGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Gossamer Bio in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the company will post earnings per shareJanuary 22, 2025 | marketbeat.comGossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 12.8% in DecemberGossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 6,120,000 shares, a decrease of 12.8% from the December 15th total of 7,020,000 shares. Based on an average daily trading volume, of 1,330,000 shares, the days-to-cover ratio is currently 4.6 days.January 19, 2025 | marketbeat.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 7, 2025 | businesswire.comGossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Up 10.0% in DecemberGossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 7,020,000 shares, a growth of 10.0% from the November 30th total of 6,380,000 shares. Based on an average daily volume of 1,290,000 shares, the days-to-cover ratio is presently 5.4 days.December 31, 2024 | marketbeat.comLeerink Partnrs Boosts Earnings Estimates for Gossamer BioGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Leerink Partnrs increased their FY2024 earnings per share estimates for Gossamer Bio in a research note issued on Monday, November 11th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.32) for thNovember 14, 2024 | marketbeat.comGossamer Bio’s Strategic Advancements and Financial Resilience Support Buy RatingNovember 13, 2024 | markets.businessinsider.comHC Wainwright Boosts Earnings Estimates for Gossamer BioGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Analysts at HC Wainwright boosted their FY2024 EPS estimates for Gossamer Bio in a research note issued to investors on Monday, November 11th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.18) per share for the yeNovember 13, 2024 | marketbeat.comGossamer Bio (GOSS) Gets a Buy from OppenheimerNovember 13, 2024 | markets.businessinsider.comIndustry Analysts Just Made A Sizeable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Revenue ForecastsNovember 12, 2024 | finance.yahoo.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 11, 2024 | businesswire.comGossamer Bio, Inc. (NASDAQ:GOSS) Just Reported And Analysts Have Been Lifting Their Price TargetsNovember 11, 2024 | finance.yahoo.comPromising Progress and Expansion Potential of Gossamer Bio’s Seralutinib Drive Buy RatingNovember 11, 2024 | markets.businessinsider.comGossamer Bio (NASDAQ:GOSS) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Monday.November 11, 2024 | marketbeat.comGossamer Bio Reports Revenue Growth Amid Strategic CollaborationsNovember 9, 2024 | markets.businessinsider.comGossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business UpdateNovember 8, 2024 | finance.yahoo.comGossamer Bio, Inc. (NASDAQ:GOSS) Sees Large Decline in Short InterestGossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) saw a large drop in short interest in October. As of October 15th, there was short interest totalling 6,950,000 shares, a drop of 10.3% from the September 30th total of 7,750,000 shares. Based on an average trading volume of 899,400 shares, the days-to-cover ratio is currently 7.7 days.October 30, 2024 | marketbeat.com Remove Ads Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address GOSS Media Mentions By Week GOSS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GOSS News Sentiment▼0.300.86▲Average Medical News Sentiment GOSS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GOSS Articles This Week▼32▲GOSS Articles Average Week Remove Ads Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RCUS News Today VIR News Today PAHC News Today MLYS News Today SYRE News Today NRIX News Today ZYME News Today AVXL News Today DAWN News Today GYRE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GOSS) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GOSS Stock Free GOSS Stock Alerts